Skip to main content

iPR Software to Acquire Minority Shares from Founder Eric Schwartzman

LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) — iPR Software, Inc., https://www.iprsoftware.com/, a Software as a Service (SaaS) company that utilizes AI-driven digital solutions for PR and Marketing professionals, announced today that Eric Schwartzman, the founder of iPressroom and a pioneer in the digital software industry, has sold his remaining minority interest in the company.  “We are grateful to Eric for his vision in founding our company and wish him continued success,” said J.D. Bowles President & CEO.  “He has been an industry champion and served many roles throughout the digital media transformation.” “I happened to be in the right place at the right time, and I saw something starting to shift,” said Schwartzman. “I’ve always had a knack for spotting change early, and...

Continue reading

Minuteman Press Franchise in Wethersfield, CT Wins Business of the Year; Acquires 42-Year Print Shop Academy Printing

WETHERSFIELD, Conn., Nov. 19, 2025 (GLOBE NEWSWIRE) — To say Mark Flannery’s first full year in business as the owner of Minuteman Press in Wethersfield, CT was productive is an understatement. Mark purchased the business in November of 2024. In just one year, Mark has grown his Minuteman Press franchise by leveraging his background in marketing and sales, making inroads in the community, and hiring the right staff. As a result, Mark and his team won the Business of the Year Award from the Wethersfield Chamber of Commerce. To wrap up his first year, Mark has also completed a key acquisition of 42-year print shop Academy Printing.Journey to Minuteman Press & Celebrating One Year Prior to Minuteman Press, Mark shares, “My background is in marketing and sales support for large corporations. I was looking at a few different...

Continue reading

Ainekko Acquires Esperanto Technologies’ Intellectual Property to Power Open-Source Edge AI Platform

Company to open-source RTL, chips, and tools to catalyze community-driven innovation in AI inference SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) — Ainekko, a startup pioneering open, software-defined AI infrastructure, today announced the acquisition of all intellectual property and select assets from Esperanto Technologies, including chip designs, software tooling, and development frameworks. The acquisition marks a major step toward Ainekko’s goal of making advanced AI infrastructure open, accessible, and adaptable, starting at the silicon level. By releasing a production-grade, many-core RISC-V architecture to the public, including RTL, reference designs, and development tools, Ainekko is laying the foundation for a new era of community-driven hardware innovation. The platform is designed to empower developers, researchers,...

Continue reading

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T program Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR⍺ Antagonist, Phase 3-ready) and TPST-1495 (Dual Ep2/4 Antagonist, Phase 2 start expected near term) The anticipated preclosing equity financing and an investment commitment from Factor Bioscience is expected to extend Tempest’s runway to mid 2027 and through potentially significant milestones Plan to proceed with execution of globally approved protocol for amezalpat in first-line HCC subject to additional resources or partnerships Matt Angel, Ph.D. to assume role of President and CEO and Stephen Brady to assume role of Chairman of the board of directors upon closing of the acquisitionBRISBANE, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) — In a transaction designed to both...

Continue reading

Form 8.3 – [IQE PLC – 18 11 2025] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IQE PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Form 8.3 – [IDOX PLC – 18 11 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IDOX PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: IDOX PLC AS AN ASSOCIATE OF THE CANACCORD...

Continue reading

P95 and Julius Clinical Merge to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World Evidence

500+ person global organization spans 25+ countries with operations across North America, Europe, Africa, Latin America, and Asia-PacificP95 and Julius ClinicalMerger to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World EvidenceLeuven, Belgium and Zeist, The Netherlands, Nov. 19, 2025 (GLOBE NEWSWIRE) — P95 and Julius Clinical today announced that they have merged to form a leading global, full-service clinical research organization (CRO) with integrated expertise across neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines. The combined organization includes more than 500 professionals in over 25 countries and delivers clinical development and real-world evidence (RWE) programs across five continents. This merger brings together the complementary strengths of...

Continue reading

Wereldhave acquires shopping center Ville2 in Charleroi, Belgium

Wereldhave N.V. (‘Wereldhave’), through Wereldhave Belgium (69% owned by Wereldhave), has reached agreement with Everbel SA, a Luxembourg family office, on the acquisition of shopping center Ville2 in Charleroi, Belgium. This acquisition is part of the LifeCentral strategy growth phase and is fully compliant with Wereldhave’s rigorous acquisition criteria, including IRR threshold, location, value creation opportunities and Full Service Center transformation potential. This acquisition further strengthens Wereldhave’s leading position in the Walloon region, where the company has been active for nearly 50 years. The total purchase price amounts to € 120m, reflecting a net initial yield of 8.0%. The transaction is expected to close in December 2025. The acquisition of Ville2, together with the disposal of De Roselaar (Roosendaal) and the...

Continue reading

Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical

Aptose Biosciences minority shareholders to receive C$2.41 in cash per share in a “go private” transaction SAN DIEGO and TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) and Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) today announced that Aptose, Hanmi and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), have entered into a definitive arrangement agreement (the “Arrangement Agreement”) pursuant to which Hanmi Purchaser will acquire all of the issued and outstanding common shares of Aptose (“Common Shares”) that are not currently owned or controlled by the Hanmi Purchasers or their respective affiliates. Hanmi has participated in multiple financings of Aptose and owns 19.93% of all outstanding...

Continue reading

Press Release – Amundi announces it has acquired 4.6% of ICG’s share capital

Press release Amundi announces it has acquired 4.6% of ICG’s share capital Paris, 19 November 2025 – Amundi announces it has acquired 4.64% of ICG’s share capital in a structured transaction, pursuant to the long-term strategic and equity partnership announced by Amundi and ICG. As part of this partnership, Amundi intends to acquire a total economic interest of 9.9% in ICG1. About Amundi Amundi, the leading European asset manager, ranking among the top 10 global players2, offers its 200 million clients – retail, institutional and corporate – a complete range of savings and investment solutions in active and passive management, in traditional or real assets. This offering is enhanced with IT tools and services to cover the entire savings value chain. A subsidiary of the Crédit Agricole group and listed on the stock exchange,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.